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Abstract
Background Dual blockade of HER2 promises increased pathological complete response (pCR) rate compared with single 
blockade in the presence of chemotherapy for HER2-positive (+) primary breast cancer. Many questions remain regarding 
optimal duration of treatment and combination impact of endocrine therapy for luminal HER2 disease.
Methods We designed a randomised phase II, five-arm study to evaluate the efficacy and safety of lapatinib and trastuzumab 
(6 weeks) followed by lapatinib and trastuzumab plus weekly paclitaxel (12 weeks) with/without prolongation of anti-HER2 
therapy prior to chemotherapy (18 vs. 6 weeks), and with/without endocrine therapy in patients with HER2+ and/or oestrogen 
receptor (ER)+ disease. The primary endpoint was comprehensive pCR (CpCR) rate. Among the secondary endpoints, pCR 
(yT0-isyN0) rate, safety, and clinical response were evaluated.
Results In total, 215 patients were enrolled; 212 were included in the full analysis set (median age 53.0 years; tumour 
size = T2, 65%; and tumour spread = N0, 55%). CpCR was achieved in 101 (47.9%) patients and was significantly higher 
in ER− patients than in ER+ patients (ER− 63.0%, ER+ 36.1%; P = 0.0034). pCR with pN0 was achieved in 42.2% of 
patients (ER− 57.6%, ER+ 30.3%). No significant difference was observed in pCR rate between prolonged exposure groups 
and standard groups. Better clinical response outcomes were obtained in the prolongation phase of the anti-HER2 therapy. 
No surplus was detected in pCR rate by adding endocrine treatment. No major safety concern was recognised by prolonging 
the anti-HER2 treatment or adding endocrine therapy.
Conclusions This study confirmed the therapeutic impact of lapatinib, trastuzumab, and paclitaxel therapy for each ER− and 
ER+ subgroup of HER2+ patients. Development of further strategies and tools is required, particularly for luminal HER2 
disease.
Keywords Anti-HER2 therapy · Lapatinib · Paclitaxel · Phase II study · Trastuzumab
Introduction
Trastuzumab has been found to prolong survival and 
reduce relapse in human epidermal growth factor receptor 
2 (HER2)+ patients with advanced and early stage breast 
cancer when used in combination with other chemotherapy 
agents and in a neoadjuvant and adjuvant setting [1–4]. In 
the sequential neoadjuvant and adjuvant settings, the NOAH 
study compared the treatment with and without trastuzumab 
in women with HER2+ breast cancer treated with a neo-
adjuvant chemotherapy regimen [4]. The 3-year event-free 
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survival was higher in the trastuzumab group than the 
non-trastuzumab group. When comparing the trastuzumab 
group with the HER2+ chemotherapy alone group, a 41% 
risk reduction of recurrence, progression, or death by tras-
tuzumab treatment was shown. Similarly, the achievement 
of higher pathological complete response (pCR) rates with 
chemotherapy plus trastuzumab has improved survival out-
comes in the neoadjuvant setting [5].
Lapatinib, a dual, reversible HER2/epidermal growth fac-
tor receptor (HER1) tyrosine kinase inhibitor, both alone 
and in combination with chemotherapy, has significantly 
improved progression-free survival in metastatic HER2+ 
breast cancer patients [6]. Synergistic interactions have 
been recognised between lapatinib and trastuzumab, owing 
to their different mechanisms of action and receptor site 
activity. Studies have shown that combined treatment with 
lapatinib and trastuzumab was more effective in terms of 
pCR than trastuzumab alone in patients with HER2+ breast 
cancer [7–9].
Results of preclinical studies suggest that cross talk 
between HER2 and oestrogen receptor (ER) signalling 
pathways in breast cancer contributes to resistance to hor-
monal therapy [10, 11]. Therefore, it was hypothesised that 
inhibiting both pathways could be more beneficial than ER 
or HER2 inhibition alone. In the TAnDEM study, postmeno-
pausal women with HER2/hormone receptor-copositive met-
astatic breast cancer were treated with anastrozole combined 
with trastuzumab, without chemotherapy. This combination 
was found to significantly improve progression-free sur-
vival, time to progression, clinical benefit rate, and overall 
response rate compared with hormone therapy alone [12]. 
Similarly, in the EGF30008 trial, women with metastatic 
breast cancer that coexpressed ER and ErbB2 were treated 
with a combination of lapatinib and letrozole, and achieved 
significantly increased progression-free survival and clini-
cal benefit rates [13]. In the TBCRC 006 trial, 66 women 
with locally advanced HER2+ and ER+ breast cancer were 
treated with neoadjuvant trastuzumab, lapatinib, and letro-
zole. This approach of targeted therapy without chemother-
apy resulted in an overall pCR rate of 27%, and of 21% in 
ER+ patients [14].
The aim of the present study (JBCRG-16 [Neo-LaTH]) 
was to evaluate the efficacy and safety of lapatinib and tras-
tuzumab therapy followed by lapatinib and trastuzumab 
plus weekly paclitaxel in Japanese patients with primary 
HER2+ breast cancer in a neoadjuvant setting. Additionally, 
we examined the effects of different periods of lapatinib and 
trastuzumab therapy (6 vs. 18 weeks) and the effects of add-
on endocrine therapy in ER+ patients.
Patients and methods
Study design
This randomised, five-arm, multicentre, open-label phase 
II trial was conducted between March 2012 and Sep-
tember 2013 in 16 centres in Japan (Fig. 1). This study 
was registered at http://www.umin.ac.jp/ctr/index -j.htm 
(UMIN000007576). The study protocol was approved by 
the ethical review boards of all the participating centres. 
All the study procedures were conducted in accordance 
with the latest version of the Declaration of Helsinki and 
the Good Clinical Practice Guideline.
Patients
Patients were eligible if they were aged between 20 and 
70 years; had a confirmed HER2+ invasive breast cancer 
by the central laboratory [immunohistochemistry score of 
3+ or positive by dual in situ hybridisation (DISH)]; and 
had primary breast cancer (T1c-3N0-1M0) with a target 
lesion of ≤ 7 cm. Further details of inclusion and exclu-
sion criteria are described in Supplementary Material S1. 
All patients provided written informed consent.
Randomisation
Randomisation, as well as the enrolment of participants 
and assigning of participants to the trial groups, was per-
formed by the registration centre in Niphix (Tokyo, Japan).
There were five comparative groups (Fig. 1) that con-
tained the following drugs: ER−, (a) lapatinib and trastu-
zumab followed by the same plus weekly paclitaxel; (b) 
prolonged lapatinib and trastuzumab followed by the same 
combined with weekly paclitaxel; ER+, (c) lapatinib and 
trastuzumab plus weekly paclitaxel, (d) lapatinib and tras-
tuzumab plus weekly paclitaxel and endocrine therapy, and 
(e) prolonged lapatinib and trastuzumab plus weekly pacli-
taxel and endocrine therapy. Groups A, C, and D received 
lapatinib and trastuzumab for 6 weeks; groups B and E, 
for 18 weeks. All groups received ongoing lapatinib and 
trastuzumab plus weekly paclitaxel for 12 weeks following 
the initial lapatinib and trastuzumab period. Some pre-
clinical [15] and clinical [16] studies have suggested that 
the combination of an aromatase inhibitor and a taxane 
could be a promising therapeutic option with an additive 
or synergistic effect. Therefore, after the initial targeted 
therapy, endocrine therapy was continued during chemo-
therapy in groups D and E.
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Procedures
Lapatinib was orally administered at 1000 mg/day during the 
initial lapatinib and trastuzumab period and at 750 mg/day 
during the lapatinib and trastuzumab plus weekly paclitaxel 
period. Trastuzumab was administered intravenously at a 
dose of 4 mg/kg in week 1, and at 2 mg/kg every week there-
after. Paclitaxel was administered by intravenous infusion at 
a dose of 80 mg/m2 every week. Groups D and E received 
additional endocrine therapy (ET), consisting of 11.25 mg 
of leuprorelin SR every 12 weeks by subcutaneous depot 
injection plus 20 mg/day of tamoxifen for premenopausal 
patients and 2.5 mg/day of letrozole for postmenopausal 
patients. The procedures are described in detail in Fig. 1 
and Supplementary Material S2.
Outcomes
The primary endpoint was comprehensive pathological com-
plete response (CpCR) rate, including residual ductal car-
cinoma in situ of the breast. The secondary endpoints were 
safety profiles and efficacy outcomes, including the clinical 
overall response rate (ORR), breast conservation rate (BCR), 
and CpCR plus ypN0. CpCR plus ypN0 was defined as the 
absence of lymph node metastasis in sentinel node biopsy 
and/or dissection performed after systemic treatment, even if 
absence of sentinel lymph node (SLN) metastasis was con-
firmed before starting therapy.
Statistical analysis
Among demographic variables, quantitative variables were 
summarised using mean, median, standard deviation, and 
maximum and minimum values. The administration of 
the study drug was summarised as the dose intensity and 
relative dose intensity descriptively using mean and stand-
ard deviation. The adverse event data were categorised by 
CTCAEv4.0 and analysed. Any patient who received lapa-
tinib treatment was included in the analysis. Regarding the 
pCR rate, point estimate and two-sided 95% confidence 
intervals (CIs) were calculated for each between-group dif-
ference in pCR rate. Secondary endpoints were analysed 
using the χ2 test or Wilcoxon test based on the type of data. 
Regarding response rate, point estimates in two-sided 95% 
CIs were calculated for each group and between-group dif-
ferences. Between-group comparisons were performed using 
the χ2 test.
ER- 
R 
(1:1) 
6 weeks 12 weeks 
18 weeks 12 weeks 
Surgery B 
6 weeks 12 weeks 
Surgery A 
R 
(1:1:1) 
6 weeks 12 weeks 
18 weeks 12 weeks 
Surgery E 
6 weeks 12 weeks 
Surgery D 
6 weeks 12 weeks 
Surgery C 
ER+ 
Trastuzumab: 4 mg/kg in week 1, 2 mg/kg every week thereaer 
Trastuzumab: 6 mg/kg every 3 weeks 
Endocrine therapy: Leuprorelin 11.25 mg  (weeks 1, 13) + TAM 20 mg/day (Premenopause), Letrozole 2.5 mg/day (Postmenopause) 
Lapanib: 1,000 mg/day → 750 mg/day 
Paclitaxel: 80 mg/m2 every week 
Fig. 1  Study design. ER oestrogen receptor, TAM tamoxifen
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We planned a sample size of 40 patients per group (total, 
200) to explore three research hypotheses, the details of 
which are provided in Supplementary Material S2. To evalu-
ate the relationship between the dose of lapatinib during the 
anti-HER2 therapy and the clinical response, a tail-oriented 
subpopulation treatment effect pattern plot (STEPP) analysis 
was performed.
Results
From 215 patients enrolled, 213 were included in the safety 
analysis set. One patient, whose tumour was found to be 
HER2-negative after starting study drug administration, was 
excluded from the full analysis set (n = 212) (Supplementary 
Material S3).
The characteristics of the patients are summarised in 
Table 1. Patients had a median age of 53.0 years (range, 
26–70 years); 65% were classified as T2 and 55% as N0. 
Among the 117 N0 patients, 35 (29.9%) underwent pre-
systemic therapy SLN biopsy. As a result, 28 patients 
(80.0%) were SLN-negative. Following successful surgery, 
10 patients underwent SLN biopsy again. No axillary metas-
tasis was found in any of these patients.
Regarding the primary study endpoint, CpCR was 
achieved in 101 (47.9%) patients. This was calculated based 
on 211 patients in the full analysis set who underwent sur-
gery (one patient elected not to undergo surgery because 
her lesion had disappeared in response to treatment). CpCR 
was significantly higher in ER− patients than in ER+ 
patients (Group A vs. Group C, P = 0.0034, Table 2 and 
Supplementary Material S4). In groups A, B, C, D, and E, 
CpCR was achieved by 65.9, 60.4, 34.1, 33.3, and 41.0% of 
patients, respectively. No significant difference was observed 
in CpCR among the groups with different durations (6 vs. 
18 weeks) of lapatinib plus trastuzumab (A vs. B, P = 0.59). 
CpCR in ER+ patients who received add-on endocrine ther-
apy was not significantly greater than that in ER+ patients 
without endocrine therapy (C vs. D, P = 0.94).
The relative dose intensities of lapatinib during the lapa-
tinib and trastuzumab period were over 90%, and during 
the lapatinib and trastuzumab plus weekly paclitaxel period 
Table 1  Baseline characteristics of the safety analysis set population
BMI body mass index, CT computed tomography, ER oestrogen receptor, FISH fluorescence in situ hybridisation,  IHC immunohistochemistry, 
MRI magnetic resonance imaging
Data presented in the table are n (%), unless otherwise stated
Group A (n = 44) Group B (n = 48) Group C (n = 41) Group D (n = 40) Group E (n = 40) All groups (n = 213)
Age (years)
 Median (range) 56.0 (33–69) 56.0 (36–69) 52.0 (32–70) 53.5 (26–66) 49.0 (28–68) 53.0 (26–70)
Menopausal status
 Premenopausal 14 (32) 18 (38) 19 (46) 20 (50) 20 (50) 91 (43)
 Postmenopausal 30 (68) 30 (63) 22 (54) 20 (50) 20 (50) 122 (57)
BMI (kg/m2)
 Median (range) 21.7 (14.7–32.6) 22.9 (17.3–37.4) 21.8 (14.7–32) 21.5 (14.1–33.7) 21.8 (17.3–35.3) 21.9 (14.1–37.4)
HER2
 IHC 3+ 43 (98) 45 (94) 37 (90) 33 (83) 37 (93) 195 (92)
 IHC 2 + , FISH+ 1 (2) 3 (6) 4 (10) 7 (17) 3 (7) 18 (8)
ER
 ER− 44 (100) 48 (100) – – – 92 (43)
 ER+ – – 41 (100) 40 (100) 40 (100) 121 (57)
T
 T1c 4 (9) 6 (13) 11 (27) 8 (20) 11 (28) 40 (19)
 T2 31 (71) 29 (60) 26 (63) 27 (68) 26 (65) 139 (65)
 T3 9 (20) 13 (27) 4 (10) 5 (13) 3 (8) 34 (16)
N
 N0 22 (50) 26 (54) 23 (56) 23 (58) 24 (60) 118 (55)
 N1 22 (50) 22 (46) 18 (44) 17 (43) 16 (40) 95 (45)
Tumour size (MRI/CT) (mm)
 Median (range) 29 (13–62) 32 (14–70) 24 (11–73) 28 (11–60) 27 (14–61) 28 (11–73)
Breast conservation thought to be possible before starting the trial
 Yes 18 (41) 17 (35) 21 (51) 14 (35) 18 (45) 88 (41)
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were around 80% (Supplementary Material S5). Grade ≥ 3 
adverse events were observed in 42.3% of patients (Supple-
mentary Material S6); the most common were neutropenia 
(19%), diarrhoea (12%), skin and subcutaneous disorders, 
elevated alanine transaminase (5% each), and paronychia 
(3%). No deaths were reported. There were no significant 
changes in the mean left ventricular ejection fraction from 
baseline in any regimen.
CpCR and CpCR + ypN0 were not improved by the 
extended lapatinib plus trastuzumab or add-on endocrine 
therapy (Table 2). ORRs evaluated by magnetic resonance 
imaging (MRI) or computed tomography (CT) were 81.8, 
81.3, 85.4, 97.4, and 92.5%; and BCRs were 63.6, 55.3, 
70.7, 53.8, and 68.4% (Supplementary Material S4). How-
ever, prolongation of lapatinib plus trastuzumab resulted in 
improved clinical efficacy (Table 2), as shown by clinical 
response in the lapatinib plus trastuzumab phase evaluated 
by MRI/CT (ORR and clinical CR). Supplementary Mate-
rial S7 shows the subpopulation treatment effect pattern plot 
analysis. The ORR increased linearly with increasing lapat-
inib dose in the lapatinib plus trastuzumab period especially 
in the ER+ cohort.
A similar tendency was observed in quasi-pCR [QpCR 
(CpCR + near pCR)]. For ER+ patients, quasi-pCR tended 
to improve with increasing lapatinib dose and add-on ET 
(Supplementary Material S8). Clinical efficacy at the last 
time point before surgery (i.e., at the end of weekly pacli-
taxel add-on period following lapatinib and trastuzumab 
period) is shown in Table 2. There was no significant differ-
ence among the five groups in terms of clinical efficacy. In 
groups B and E, the benefit from the add-on weekly pacli-
taxel tended to be small.
From the experimental analyses regarding the percent 
change in maximum tumour size from pre-treatment to end 
of treatment measured by MRI/CT during the time course 
and relationship between pathological response (Fig. 2), 
among ER− patients, the prolongation of the lapatinib plus 
trastuzumab phase seemed to be important for achieving 
pCR. Conversely, among ER+ patients, pCR was mainly 
influenced by the reduction effect through the addition of 
paclitaxel. This tendency was observed especially in groups 
C and D. In Group B, at 18 weeks of lapatinib plus trastu-
zumab therapy, the percent change in maximum tumour size 
was 25.1% (95% CI 13.5–36.8%) in patients with pCR and 
64.5% (95% CI 45.7–83.4%) in patients without pCR, indi-
cating a significant reduction in the patients with pCR. In 
the hormone receptor-positive groups C and D, the percent 
change in maximum tumour size at the end of the lapatinib 
plus trastuzumab plus weekly paclitaxel therapy (at the end 
of all the cycles) was significantly different between patients 
with and without pCR. In Group C, the percent change in 
maximum tumour size was 17.4% (95% CI 4.4–30.5%) 
in patients with pCR and 49.0% (95% CI 37.1–60.9%) in 
patients without pCR. In Group D, the ratio was 15.7% (95% 
CI 2.2–29.3%) in patients with pCR and 34.9% (95% CI 
25.2–44.6%) in patients without pCR.
Table 2  Comprehensive pathological complete response and clinical efficacy
CpCR comprehensive pathological complete response, CR complete response, ER oestrogen receptor, La + T lapatinib plus trastuzumab, ns not 
significant, ORR overall response rate, PR partial response
a There were no significant differences when comparing A vs. B, C vs. D vs. E, and A + C + D vs. B + E (P > 0.05)
b Group A vs C: P = 0.0034
c Group A vs C: P = 0.0030
d CR rate in La + T period: A vs B, P < 0.05; D vs E, P < 0.05; C vs D vs E, P < 0.05; A + C + D vs B + E, P < 0.05
e PR rate in La + T period: A vs B, ns; D vs E, ns; C vs D vs E, ns; A + C + D vs B + E, ns
f ORR in La + T period: A vs B, ns; D vs E, ns; C vs D vs E, P < 0.05; A + C + D vs B + E, P < 0.05
g There was no significant difference among the five groups in terms of clinical efficacy
Comprehensive pathological 
complete response (%)a
Clinical efficacy (%)
CpCR (yT0-is) CpCR (yT0-
is) + ypN0
CR in La + Td PR in La + Te ORR in La + Tf Additional clinical 
benefit from pacli-
taxel
Clinical efficacy at the last 
time point before  surgeryg
ER−
 A 65.9b 61.4c 4.5 45.5 50.0 29.5 79.5
 B 60.4 54.2 22.9 45.8 68.7 10.4 79.1
ER+
 C 34.1b 29.3c 4.9 36.6 41.5 41.4 82.9
 D 33.3 30.8 0 48.7 48.7 46.2 95.9
 E 41 30.8 15 52.5 67.5 22.5 90.0
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Supplementary Material S9 shows the changes in tumour 
diameter from baseline to the end of treatment. Among 
ER− patients, those who responded to treatment early in 
the lapatinib plus trastuzumab phase tended to achieve pCR. 
Among ER+ patients, there was no significant correlation 
between clinical efficacy and pathological efficacy.
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0.0
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60.0
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Group A
Group B
Group C
Group E
0.0
20.0
40.0
60.0
80.0
100.0
start La+T(6 wks) La+T(18 wks) La+T+wP
0.0
20.0
40.0
60.0
80.0
100.0
start La+T(6 wks) La+T+wP
Group D
0.0
20.0
40.0
60.0
80.0
100.0
start La+T(6 wks) La+T+wP
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Discussion
In the Neo-LaTH study, the efficacy and safety of lapatinib 
and trastuzumab therapy followed by lapatinib and trastu-
zumab plus weekly paclitaxel in primary HER2+ breast can-
cer patients were equivalent to that in two previous studies 
[7, 8]. Regarding the effect of the extension of lapatinib plus 
trastuzumab treatment period from 6 to 18 weeks and addi-
tion of endocrine therapy, the pCR rates (primary endpoint) 
were not improved by the extended treatment. Although 
the primary endpoint did not match the expected result, the 
secondary clinical efficacy indicates that in ER− patients 
finally achieving pCR, combined HER2 blockade therapy 
alone, which was given before the initiation of the weekly 
paclitaxel treatment, tended to induce a greater reduction 
due to the prolongation of the therapy from 6 to 18 weeks. 
This suggests that in ER− patients who respond to combined 
HER2 blockade therapy, the prolongation of the treatment 
period can lead to the avoidance of the future use of cyto-
toxic anti-cancer drugs. The comparison of Groups D and E 
with combined hormone therapy showed that among ER+ 
patients, the proportion of patients with complete response 
or partial response tended to be greater when the treatment 
period was prolonged to 18 weeks. However, the differ-
ence was not as great as that observed in ER− patients. Our 
findings are in agreement with previous chemotherapy-free 
regimens (the NeoSPHERE [17] and the NeoALTTO [7] 
studies). Thus, the results of the chemotherapy-free phase 
of Neo-LaTH support the concept that dual HER2 blockage 
can lead to decreased length of chemotherapy regimens, and 
that a proportion of HER2+ tumours could potentially be 
eradicated with chemotherapy-free regimens.
Changes in tumour diameter tended to be larger after add-
on endocrine therapy and extended treatment with lapatinib 
and trastuzumab in ER+ patients in the present study. Simi-
larly, 40% of patients in the TBCRC 006 study achieved pCR 
by 12 weeks of dual HER2 blockage with lapatinib plus 
trastuzumab despite having large initial tumour size [14]. 
Together, these results suggest that the changes in tumour 
diameter increase in proportion to the extended period of 
molecularly targeted drug therapy. Overall clinical response 
rates were also significantly higher in the 18-week group 
rather than the 6-week group. Our findings are useful for 
the future exploration of chemotherapy-free anti-HER2 regi-
mens for women who cannot receive cytotoxic drugs.
We hypothesised that the addition of endocrine therapy 
may increase the pCR rate in ER+ luminal HER2 subtype. 
Regimen D showed high overall clinical response rate 
(97.4%) with 31.6% of clinical CR. In the regimen-E group, 
it was also as high as 92.5% with 37.5% of clinical CR, indi-
cating that the endocrine therapy combination would be able 
to provide high levels of clinical response. However, pCR in 
ER+ patients who received add-on endocrine therapy was 
not significantly greater than that in ER+ patients without 
endocrine therapy. These results were unexpected since 
improved pCR rates had been achieved previously in the 
TBCRC 006 study of women with locally advanced HER2+ 
and ER+ breast cancer who were treated with neoadjuvant 
trastuzumab, lapatinib, and letrozole [14]. To increase the 
pCR rate against luminal HER2 disease, further strategies 
need to be developed.
With regard to toxicity, the frequencies of grade 3/4 
adverse events in the Neo-LaTH study were similar to those 
observed in other studies. The relative dose intensity of 
lapatinib was also similar to that in previous results. From 
the STEPP analysis, a relationship was revealed between 
the administration dose of lapatinib during the anti-HER2 
therapy phase and the clinical response.
The strength of the present study is the novelty of the 
study design, which allowed the prolonged duration of dual 
HER2 blockage with lapatinib plus trastuzumab in the neo-
adjuvant setting. This study had several potential limitations, 
in particular those inherent to phase II open-label studies. 
However, current outcomes may be informative for future 
studies, and correlative translational research is ongoing 
to analyse molecular mechanisms of tumour responses and 
therapeutic resistance. Another limitation is the small sam-
ple size; however, this was determined on a statistical basis, 
and it is important to verify a hypothesis in a small sample 
size study.
In conclusion, the findings of the present study confirmed 
the efficacy and safety of lapatinib and trastuzumab followed 
by lapatinib plus trastuzumab plus weekly paclitaxel for the 
treatment of HER2+ invasive breast cancer in Japanese 
patients. These results are relevant for clinicians considering 
the optimal duration of preoperative anti-HER2 treatment for 
HER2+ disease and the combination with endocrine therapy 
for luminal HER2 subtype. Further analysis of disease-free 
survival/overall survival in conjunction with biomarker stud-
ies is necessary to explore the therapeutic impact.
Fig. 2  Percent change in maximum tumour size from pre-treatment 
to end of treatment measured by MRI/CT during the time course and 
relationship between pathological response per group. The vertical 
axis shows the percent change in maximum tumour size from pre-
treatment to end of treatment measured by MRI or CT. Considering 
that tumour sizes varied among patients, the mean maximum tumour 
size was set at 100% at the study start. Then, the percent change in 
maximum tumour size was calculated at the end of treatment. The 
percent change values shown in the graph represent the percentage 
of the tumour size remaining at the end of treatment. The horizon-
tal axis is the timing of the examination course. Red column: patients 
who achieved pathological complete response (pCR); blue column: 
patients with residual invasive disease (non-pCR). MRI magnetic 
resonance imaging, CT computed tomography, La lapatinib, T trastu-
zumab, wP weekly paclitaxel
◂
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